WO2012006634A3 - Prostate specific antigen (psa) peptide therapy - Google Patents
Prostate specific antigen (psa) peptide therapy Download PDFInfo
- Publication number
- WO2012006634A3 WO2012006634A3 PCT/US2011/043598 US2011043598W WO2012006634A3 WO 2012006634 A3 WO2012006634 A3 WO 2012006634A3 US 2011043598 W US2011043598 W US 2011043598W WO 2012006634 A3 WO2012006634 A3 WO 2012006634A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- psa
- specific antigen
- prostate specific
- peptide therapy
- peptide
- Prior art date
Links
- 102000007066 Prostate-Specific Antigen Human genes 0.000 title 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A61K39/464494—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/58—Prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
The present invention is directed to compositions and methods for treating prostate cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/413,242 US8557777B2 (en) | 2010-07-09 | 2012-03-06 | Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36309110P | 2010-07-09 | 2010-07-09 | |
US61/363,091 | 2010-07-09 | ||
US201061426321P | 2010-12-22 | 2010-12-22 | |
US61/426,321 | 2010-12-22 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/413,242 Continuation-In-Part US8557777B2 (en) | 2010-07-09 | 2012-03-06 | Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012006634A2 WO2012006634A2 (en) | 2012-01-12 |
WO2012006634A3 true WO2012006634A3 (en) | 2012-05-31 |
Family
ID=45441875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/043598 WO2012006634A2 (en) | 2010-07-09 | 2011-07-11 | Prostate specific antigen (psa) peptide therapy |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012006634A2 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
WO2013142390A1 (en) * | 2012-03-21 | 2013-09-26 | Gtx, Inc. | Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors |
BR112014032728A2 (en) | 2012-06-27 | 2017-11-28 | Berg Llc | use of markers in the diagnosis and treatment of prostate cancer |
WO2014047085A2 (en) * | 2012-09-20 | 2014-03-27 | Rongfu Wang | Prostate-specific tumor antigen and uses thereof |
EP3292873B1 (en) | 2013-02-22 | 2019-05-01 | CureVac AG | Combination of vaccination and inhibition of the pd-1 pathway |
DK2958588T3 (en) * | 2013-02-22 | 2017-11-20 | Curevac Ag | Combination of vaccination and inhibition of PD-1 pathway |
AU2014292926B2 (en) | 2013-07-25 | 2020-03-05 | Exicure Operating Company | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
US10568898B2 (en) | 2013-08-13 | 2020-02-25 | Northwestern University | Lipophilic nanoparticles for drug delivery |
US10307472B2 (en) | 2014-03-12 | 2019-06-04 | Curevac Ag | Combination of vaccination and OX40 agonists |
CN106535876B (en) | 2014-06-04 | 2020-09-11 | 埃克西奎雷股份有限公司 | Multivalent delivery of immunomodulators through liposomal spherical nucleic acids for prophylactic or therapeutic applications |
US10539566B2 (en) | 2014-12-08 | 2020-01-21 | Berg Llc | Use of markers including filamin A in the diagnosis and treatment of prostate cancer |
EP3240801B1 (en) * | 2014-12-31 | 2021-01-20 | Checkmate Pharmaceuticals, Inc. | Combination tumor immunotherapy |
AU2016271018A1 (en) * | 2015-05-29 | 2017-11-30 | Dynavax Technologies Corporation | Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer |
JP2019521652A (en) * | 2016-05-06 | 2019-08-08 | イグジキュア, インコーポレーテッドExicure, Inc. | TLR9 agonist of globular nucleic acid |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807978A (en) * | 1995-06-07 | 1998-09-15 | Kokolus; William J. | Immunogenic peptides of prostate specific antigen |
CA2389176A1 (en) * | 1999-10-28 | 2001-05-17 | Immunolytics Inc. | A method and composition for treating prostate cancer |
CA2468258A1 (en) * | 2001-11-30 | 2003-06-12 | Jeffrey Schlom | Peptide agonists of prostate-specific antigen, and uses therefor |
US6689355B2 (en) * | 2000-05-11 | 2004-02-10 | Altarex Corp. | Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells |
CA2319252C (en) * | 1998-01-21 | 2004-11-30 | Brigham And Women's Hospital, Inc. | Circulating insulin-like growth factor-i and prostate cancer risk |
US7288636B2 (en) * | 1997-04-30 | 2007-10-30 | Hybritech Incorporated | Forms of prostate specific antigens and methods for their detection |
CA2731823A1 (en) * | 2008-07-25 | 2010-01-28 | The Johns Hopkins University | Detection of prostate cancer using psa glycosylation patterns |
CA2748823A1 (en) * | 2009-01-06 | 2010-07-15 | Source Precision Medicine, Inc. D/B/A Source Mdx | Gene expression profiling for the identification, monitoring, and treatment of prostate cancer |
-
2011
- 2011-07-11 WO PCT/US2011/043598 patent/WO2012006634A2/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807978A (en) * | 1995-06-07 | 1998-09-15 | Kokolus; William J. | Immunogenic peptides of prostate specific antigen |
US7288636B2 (en) * | 1997-04-30 | 2007-10-30 | Hybritech Incorporated | Forms of prostate specific antigens and methods for their detection |
CA2319252C (en) * | 1998-01-21 | 2004-11-30 | Brigham And Women's Hospital, Inc. | Circulating insulin-like growth factor-i and prostate cancer risk |
CA2389176A1 (en) * | 1999-10-28 | 2001-05-17 | Immunolytics Inc. | A method and composition for treating prostate cancer |
US6689355B2 (en) * | 2000-05-11 | 2004-02-10 | Altarex Corp. | Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells |
CA2468258A1 (en) * | 2001-11-30 | 2003-06-12 | Jeffrey Schlom | Peptide agonists of prostate-specific antigen, and uses therefor |
CA2731823A1 (en) * | 2008-07-25 | 2010-01-28 | The Johns Hopkins University | Detection of prostate cancer using psa glycosylation patterns |
CA2748823A1 (en) * | 2009-01-06 | 2010-07-15 | Source Precision Medicine, Inc. D/B/A Source Mdx | Gene expression profiling for the identification, monitoring, and treatment of prostate cancer |
Also Published As
Publication number | Publication date |
---|---|
WO2012006634A2 (en) | 2012-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012006634A3 (en) | Prostate specific antigen (psa) peptide therapy | |
EP2714081A4 (en) | Methods, compositions, and kits for the treatment of cancer | |
WO2012078688A3 (en) | Humanized antibodies to liv-1 and use of same to treat cancer | |
WO2011083090A3 (en) | Methods for treating breast cancer | |
IN2014KN00848A (en) | ||
BR112013002012A2 (en) | Methods and Compositions for Liver Cancer Therapy | |
NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
EP2734207A4 (en) | Novel compositions and methods for treating prostate cancer | |
SG194701A1 (en) | Anti-cd40 antibodies and methods of use | |
WO2012170776A3 (en) | Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy | |
NZ584042A (en) | Use of mva to treat prostate cancer | |
EA201201000A1 (en) | METHODS OF TREATMENT OF COLORECTAL CANCER | |
AU2012335543A8 (en) | HER3 antibodies and uses thereof | |
WO2012024530A3 (en) | Therapeutic peptide-polymer conjugates, particles, compositions, and related methods | |
MX2011010955A (en) | Adjuvant cancer therapy. | |
NZ611785A (en) | Anti-notch1 antibodies | |
MY157341A (en) | Methods and compositions for treating lung cancer | |
WO2011129936A3 (en) | Compositions and methods for the prevention and treatment of cancer | |
MX2012013875A (en) | Peripheral blood sparc antibodies and uses thereof. | |
WO2012079878A3 (en) | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof | |
MX2014001766A (en) | Neuregulin antibodies and uses thereof. | |
ZA201300762B (en) | Novel combination therapy for the treatment of cancer | |
WO2013072901A3 (en) | Compositions and methods for treating glioma | |
WO2011097166A9 (en) | Combination therapy for treating cancer comprising an igf-1r inhibitor and an hdac inhibitor | |
EP2635273A4 (en) | Isoflavonoid compositions and methods for the treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11804483 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11804483 Country of ref document: EP Kind code of ref document: A2 |